NYSE American - Delayed Quote USD

AEON Biopharma, Inc. (AEON)

4.7200 +0.0600 (+1.29%)
At close: April 22 at 4:00 PM EDT
4.9500 +0.23 (+4.87%)
Pre-Market: 4:30 AM EDT
Loading Chart for AEON
DELL
  • Previous Close 4.6600
  • Open 4.8600
  • Bid --
  • Ask 12.5000 x 1000
  • Day's Range 4.5100 - 5.1400
  • 52 Week Range 3.3700 - 17.1700
  • Volume 72,426
  • Avg. Volume 62,712
  • Market Cap (intraday) 179.928M
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.

www.aeonbiopharma.com

10

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AEON

Performance Overview: AEON

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AEON
34.44%
S&P 500
5.05%

1-Year Return

AEON
--
S&P 500
10.01%

3-Year Return

AEON
--
S&P 500
10.01%

5-Year Return

AEON
--
S&P 500
10.01%

Compare To: AEON

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AEON

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    179.93M

  • Enterprise Value

    175.05M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -3.62

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -374.77%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -36.63M

  • Diluted EPS (ttm)

    -0.9700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.16M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -25.48M

Research Analysis: AEON

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: AEON

Fair Value

4.7200 Current
 

Dividend Score

0 Low
AEON
Sector Avg.
100 High
 

Hiring Score

0 Low
AEON
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
AEON
Sector Avg.
100 High
 

People Also Watch